Acceleron Pharma Inc. (XLRN)

Merck stock jumped Monday after a drug its acquired for billions scored a "must-win" in patients with a rare blood pressure condition. The post Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout appeared first on Investor's Business Daily.

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“Avoro,” “we” or “us”) beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron,” “XLRN” or the “Company”), making Avoro one of the Company's most significant shareholders. Avoro today issued the following statement reiterating why it believes that shareholders sh

There's nothing to worry about with a recent delay.

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds (“Avoro,” “we” or "us") beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron”, “XLRN” or the “Company”), making Avoro one of the Company's most significant shareholders. Avoro today released a detailed presentation outlining why shareholders should not tender t

Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today reported financial results for the third quarter ended September 30, 2021. Corporate Highlights On September 30, Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. announced that the companies entered into a defi

NEW YORK, Nov. 1, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Dawson Geophysical Company (NASDAQ: DWSN) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dawson Geophysical Company (NASDAQ: DWSN) in connection with the proposed acquisition of DWSN by a subsidiary of Wilks Brothers, LLC.

Merck & Co Inc (NYSE: MRK) revealed that it had temporarily withdrawn its premerger notification and report form. The company said it plans to refile today.

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq:XLRN) (“Acceleron”, “XLRN” or the “Company”) together with certain of its affiliates and managed funds (“Avoro,” “we” or "us"), making it one of the Company's most significant shareholders. Avoro today issued an open letter to fellow Acceleron shareholders further detailing why the pr

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $160 million for the third quarter ended September 30, 2021. Net sales of REBLOZYL for the third quarter include approximat

NEW YORK, Oct. 22, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP305 Broadway, 7th Floor New York, NY  10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Meredith Corporation (NYSE: MDP) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Meredith Corporation (NYSE: MDP) in connection with the proposed acquisition of the company by IAC/InterActiveCorp.  Under the terms of the merger agreement, MDP shareholders will receive $42.18 per share in cash for each share of MDP common stock that they hold.

Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed to buy the biotechnology company for $11.5 billion, Bloomberg reported citing people with knowledge of the matter. Bristol-Myers holds an 11.5% stake in Acceleron.

JERSEY, Channel Islands--(BUSINESS WIRE)--Darwin Global Management Limited (“Darwin Global”), a long-term investor in the biotechnology and pharmaceutical sector and beneficial owner of 2,345,620 shares of common stock of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron” or the “Company”), representing approximately 3.84% of the total outstanding shares of the Company's common stock, today issued the following letter to Acceleron shareholders. In the letter, Darwin Global urges shareholders not

NEW YORK--(BUSINESS WIRE)-- #Acceleron--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Acceleron Pharma Inc. (NASDAQ: XLRN) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Merck & Co., Inc. (NYSE: MRK). Click here to learn more and participate in the action. On September 30, 2021, Acceleron announced that it had entered int

NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Acceleron Pharma Inc. ( XLRN ) relating to its proposed acquisition by Merck & Co., Inc. Under the terms of the agreement, XLRN shareholders are expected to receive $180.00 in cash per share they own. The investigation focuses on whether Acceleron Pharma Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

Investment management firm Holocene Advisors said it will not tender its shares in Acceleron Pharma Inc into Merck & Co's proposed $180 per share offer for the drugmaker, as it significantly undervalues the company.